<div>
                                <figure class="article-image__container">
                                    
                                    
                                    
                                    <img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/12/shutterstock_2270640607-430x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="430" height="241" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/12/shutterstock_2270640607-430x241.jpg"/>
                                    
                                    <figcaption>Genmab’s CEO Jan van de Winkel said investments will be focused in other areas of the company’s late-stage pipeline. Image credit: claudenakagawa via Shutterstock.com.</figcaption>
                                </figure>
                            </div>
                                             
     
<p>Genmab has discontinued development of acasunlimab, a bispecific antibody that was in mid and late-stage trials for solid tumours, including non-small cell lung cancer (NSCLC).</p>



<p>Genmab remained brief on details, saying the decision was made as part of a “strategic focus on the most value‑creating opportunities” in its pipeline. The pharma company also conducted a “thorough assessment of the evolving competitive landscape”, which resulted in the acasunlimab programme being axed. The pipeline prioritisation move is not expected to impact the company’s full‑year 2025 financial guidance.</p><div>
<div id="div-gpt-ad-6065588-4"></div>
  
</div><div><div>
                   <div><h3>Go deeper with GlobalData</h3><ul><li><div><figure><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></figure></div><div><div>Reports 
                                                                
                                                                    
                                                                    
                                                                
                                                            </div><h4>LOA and PTSR Model - Ascrinvacumab in Liver Cancer </h4></div> </li><li><div><figure><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></figure></div><div><div>Reports 
                                                                
                                                                    
                                                                    
                                                                
                                                            </div><h4>LOA and PTSR Model - Pacmilimab in Non-Small Cell Lung Cancer </h4></div> </li></ul> <div>
                    <h5>
                                                Go deeper with GlobalData
                                            </h5>
                    <p>
                        The gold standard of business intelligence.
                    </p>
                    <p>
                            Find out more
                            
                                
                            
                        
                    </p>
                </div>
                </div></div><section><figure><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></figure><h4> Discover B2B Marketing That Performs </h4><p>
						Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
					</p><p>
							Find out more </p></section></div>



<p>While Genmab stated that the cancer candidate’s clinical profile has been encouraging, the company will instead pivot its focus to other oncology antibodies. This includes Epkinly (epcoritamab), petosemtamab and rinatabart sesutecan (Rina‑S), which are in late-stage trials. The company only gained access to petosemtamab recently via its $8bn acquisition of Merus in September.</p><div id="slot-one"></div><div id="Sgpollsputhere"></div>



<p>Genmab’s CEO Jan van de Winkel said: “Although the data have been encouraging, the compelling opportunities we see in our late‑stage pipeline led us to focus our investments where we believe we can deliver the greatest benefit for patients and shareholders.”</p>



<p>In 2024, Genmab assumed full development and commercialisation rights to acasunlimab after its collaboration partner BioNTech decided not to advance the asset. Acasunlimab is a bispecific antibody designed to ‌produce an anti-tumour response by targeting both PD-L1 and 4-1BB.</p>



<p>Until now, acasunlimab was being evaluated in combination with MSD’s Keytruda (pembrolizumab) for NSCLC teratment in a Phase III trial (NCT06635824). Data from a Phase II trial in this patient population reported in June 2024 demonstrated a 12-month median overall survival (OS) of 17.5 months.</p><div> 
                         <div>


            <div>

                <img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/>
            </div>


            <div>

                <span class="gdm-company-profile-unit__form-excerpt">GlobalData Strategic Intelligence</span>
 <div id="gdm-form-wrapper">



                    <h1>
                        US Tariffs are shifting - will you react or anticipate?
                    </h1>
                    <p>Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.</p>
                    <span class="gdm-company-profile-unit__text">By GlobalData</span>
                
          </div>
          </div>  
           </div> Learn more about Strategic Intelligence</div>



<p>Acasunlimab was also in Phase II development for melanoma and Phase I development for solid tumours.  </p>



<p>William Blair analyst Matt Phipps said: “We believe this is the right decision, given recent deterioration of the overall survival curve from the Phase II trial with longer follow-up, and it does not detract from what we view as one of the best opportunities in large-cap biotech going into 2026, with key pivotal readouts for Epkinly, Rina-S, and petosemtamab. With potential for $8bn in combined peak sales for the company’s three lead assets, we see significant upside for Genmab.”</p><div id="slot-two"></div>
<div id="slot-three"></div><p></p>



<div>
    
</div>



                   
               <div>
                 <h2>Pharmaceutical Technology Excellence Awards - Nominations Closed</h2>
                 <p>Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.
<br/>
<br/>
<strong>Excellence in Action</strong>
<br/>Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.</p>
Discover the Impact

             </div>

GMAB

<p>Genmab has discontinued the development of acasunlimab, a bispecific antibody for lung cancer, after a strategic review of its pipeline. The company will focus on other oncology candidates, including Epkinly and petosemtamab, which are in late-stage trials. CEO Jan van de Winkel emphasized the need to prioritize investments in high-value opportunities. Despite the decision, Genmab's financial guidance for 2025 remains unchanged. Analyst Matt Phipps supports the move, citing concerns over the survival data from acasunlimab's trials, while highlighting the potential of Genmab's other assets.</p>

Genmab shelves Phase III lung cancer candidate